Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Single-Drug Treatment For Children With Refractory or Recurrent Hepatoblastoma

NCT00287976 is registered in ClinicalTrials.gov with Children's Cancer and Leukaemia Group as lead sponsor.

NCT NCT00287976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00287976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Single-Drug Treatment For Children With Refractory or Recurrent Hepatoblastoma
Lead sponsor
Children's Cancer and Leukaemia Group
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2003
Completion date
Not reported
Enrollment
30 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer